About Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300
Debt
Debt-to-Equity Ratio0.17%
Current Ratio10.98%
Quick Ratio10.99%
Price-To-Earnings
Trailing P/E Ratio-2.83
Forward P/E Ratio-3.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales221.69
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book2.43
Profitability
EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-65.72%
Return on Assets-59.20%
Miscellaneous
Employees81
Outstanding Shares14,170,000
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings data on Wednesday, March, 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.34. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $6.38 million. Xenon Pharmaceuticals had a negative return on equity of 65.72% and a negative net margin of 9,872.67%. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
3 brokers have issued twelve-month price objectives for Xenon Pharmaceuticals' stock. Their predictions range from $5.00 to $9.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $6.6667 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Avadel Pharmaceuticals (AVDL), Savara (SVRA), Minerva Neurosciences (NERV), Selecta Biosciences (SELB), Syndax Pharmaceuticals (SNDX), Kindred Biosciences (KIN), Cue Biopharma (CUE), Mustang Bio (MBIO), Catalyst Pharmaceuticals (CPRX), Athersys (ATHX), Bellicum Pharmaceuticals (BLCM), ArQule (ARQL), resTORbio (TORC), Ovid Therapeutics (OVID) and Chimerix (CMRX).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Michael M. Tarnow, Chairman of the Board (Age 71)
- Ian C. Mortimer CPA, President, Chief Financial Officer, Chief Operating Officer (Age 42)
- Simon Neil Pimstone Ph.D., Chief Executive Officer, Director (Age 48)
- James R. Empfield, Senior Vice President - Drug Discovery
- Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development (Age 54)
- Charles M. Cohen Ph.D., Vice President - Biology (Age 66)
- Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development (Age 55)
- Karen G. Corraini J.D., General Counsel and Corporate Secretary (Age 60)
- Mohammad Azab, Director (Age 59)
- Steven R Gannon, Director (Age 55)
Has Xenon Pharmaceuticals been receiving favorable news coverage?
News headlines about XENE stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Xenon Pharmaceuticals earned a coverage optimism score of 0.19 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.28 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $4.85.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $71.57 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Xenon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 37.46%. The high price target for XENE is $9.00 and the low price target for XENE is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.6667 | $6.6667 | $5.00 | $8.1667 |
| Price Target Upside: | 37.46% upside | 36.05% upside | 66.67% upside | 172.22% upside |
Xenon Pharmaceuticals (NASDAQ:XENE) Consensus Price Target History
Xenon Pharmaceuticals (NASDAQ:XENE) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Xenon Pharmaceuticals (NASDAQ:XENE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 64.64%
Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/15/2017 | Mohammad Azab | Director | Buy | 15,000 | $2.22 | $33,300.00 | |  |
| 9/22/2017 | Mohammad Azab | Director | Buy | 10,000 | $2.95 | $29,500.00 | 21,210 | |
| 8/18/2017 | Mohammad Azab | Director | Buy | 6,335 | $2.90 | $18,371.50 | 12,898 | |
| 8/18/2017 | Raymond Winquist | Insider | Buy | 1,000 | $3.00 | $3,000.00 | 1,000 | |
| 8/15/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 18,858 | $2.41 | $45,447.78 | | |
| 8/15/2017 | James R Empfield | SVP | Buy | 10,000 | $2.48 | $24,800.00 | 10,000 | |
| 8/15/2017 | Value Fund L P Biotechnology | Insider | Buy | 60,202 | $2.61 | $157,127.22 | | |
| 8/14/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 41,344 | $2.70 | $111,628.80 | | |
| 8/14/2017 | Michael R Hayden | Director | Buy | 15,000 | $2.75 | $41,250.00 | 161,187 | |
| 8/11/2017 | Steven Gannon | Director | Buy | 15,000 | $2.82 | $42,300.00 | 15,000 | |
| 8/10/2017 | Ian Mortimer | CFO | Buy | 15,000 | $2.88 | $43,200.00 | 6,000 | |
| 8/10/2017 | Richard H Scheller | Director | Buy | 7,000 | $2.85 | $19,950.00 | 7,000 | |
| 8/10/2017 | Simon N Pimstone | CEO | Buy | 6,000 | $2.90 | $17,400.00 | 217,847 | |
| 8/8/2017 | Gary Patou | Director | Buy | 5,000 | $3.00 | $15,000.00 | 12,028 | |
| 6/27/2017 | Value Fund L P Biotechnology | Insider | Buy | 85,461 | $4.00 | $341,844.00 | | |
| 6/22/2017 | Value Fund L P Biotechnology | Insider | Buy | 20,411 | $4.00 | $81,644.00 | | |
| 6/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 26,408 | $3.84 | $101,406.72 | | |
| 6/7/2017 | Value Fund L P Biotechnology | Insider | Buy | 358,698 | $3.81 | $1,366,639.38 | | |
| 12/15/2016 | Frank A Holler | Director | Sell | 30,000 | $7.85 | $235,500.00 | 115,869 | |
| 8/19/2016 | Frank A Holler | Director | Sell | 11,938 | $7.65 | $91,325.70 | 145,869 | |
| 8/18/2016 | Frank A Holler | Director | Sell | 18,062 | $7.93 | $143,231.66 | 169,006 | |
| 6/24/2016 | Ian Mortimer | CFO | Buy | 5,300 | $6.22 | $32,966.00 | 1,000 | |
| 9/24/2015 | Y. Paul Goldberg | VP | Sell | 22,149 | $8.88 | $196,683.12 | 6,000 | |
(Data available from 1/1/2013 forward)
Xenon Pharmaceuticals (NASDAQ XENE) News Headlines
| Source: |
|
Xenon Pharmaceuticals (NASDAQ:XENE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Xenon Pharmaceuticals (NASDAQ:XENE) Income Statement, Balance Sheet and Cash Flow Statement
Xenon Pharmaceuticals (NASDAQ XENE) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
